These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 991731)

  • 1. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
    Mertz DP
    Dtsch Med Wochenschr; 1976 Aug; 101(35):1288-92. PubMed ID: 782809
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
    Matzkies F
    Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].
    Mertz DP
    Fortschr Med; 1983 May; 101(18):851-3. PubMed ID: 6862346
    [No Abstract]   [Full Text] [Related]  

  • 5. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
    Matzkies F; Neuwirth R; Berg G
    Fortschr Med; 1976 Sep; 94(26):1427-9. PubMed ID: 976920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Mertz DP
    Med Klin; 1977 Apr; 72(15):664-8. PubMed ID: 857138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
    Arntz HR; Dreykluft HR; Leonhardt H
    Fortschr Med; 1979 Jul; 97(27):1212-4. PubMed ID: 457017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Normurat (benzbromaron) in the treatment of gout].
    Bosmanský K; Trnavský K
    Z Rheumatol; 1979; 38(9-10):342-8. PubMed ID: 525067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Uric acid lowering effects of benzbromarone (Harolan) by increasing uric acid excretion].
    Fortschr Med; 1979 May; 97(17):835-6. PubMed ID: 437646
    [No Abstract]   [Full Text] [Related]  

  • 11. [Uric-acid reduction with high allopurinol dosages (author's transl)].
    Mertz DP; Loewer H
    Dtsch Med Wochenschr; 1979 Mar; 104(9):324-5. PubMed ID: 761542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness and tolerance of long-term uricosuric treatment].
    Berg H
    Z Gesamte Inn Med; 1990 Dec; 45(23):719-20. PubMed ID: 2102029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
    Matzkies F
    Fortschr Med; 1983 May; 101(20):953-9. PubMed ID: 6873850
    [No Abstract]   [Full Text] [Related]  

  • 14. [Allomaron in hyperuricemia and gout].
    Barsom S
    ZFA (Stuttgart); 1979 Aug; 55(24):1336-40. PubMed ID: 539082
    [No Abstract]   [Full Text] [Related]  

  • 15. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
    Mertz DP
    MMW Munch Med Wochenschr; 1978 Oct; 120(42):1387-90. PubMed ID: 101792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
    Mertz DP; Borner K
    Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
    [No Abstract]   [Full Text] [Related]  

  • 18. [The effect of benzbromaron in gout patients with limited kidney function].
    Kuzmits R; Bresnik W; Müller MM
    Fortschr Med; 1979 Nov; 97(44):2057-61. PubMed ID: 511087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect on uric acid and other laboratory parameters. A long-term study].
    Dorn M
    ZFA (Stuttgart); 1982 Feb; 58(5):296-300. PubMed ID: 7043937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.